ArticleScientific reports2026
Hepatitis B immune escape and drug resistance mutations among blood donors in Gabon during the year 2022.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus (HBV) and specifically occult HBV infection (OBI) remains concerning in transfusion medicine in many countries. This study aimed to determine the burden of overt and occult HBV infections and characterize the circulating viral genotypes among blood donors in Gabon. A facility-based study was conducted among blood donors at the Gabon National Blood Transfusion Centre in 2022. Screening for HBsAg and anti-HBc was done using ELISA; characterization of OBI (defined serologically as HBsAg- but anti-HBc+) was done using HBV DNA viral load (VL); and HBV Pol/S sanger-sequencing was performed for the analysis of immune-escape and drug resistance mutations. Data were analyzed with p < 0.05 considered significant. Overall, 283 participants were enrolled: 218 (77.0%) males, median age 31 (26–35) years and 264 (93.3%) frequent donors. HBV seropositivity revealed 25.1% (71/283) overt infection (i.e. HBsAg + and anti-HBc+) and 5.7% (16/283) OBI (HBsAg- but anti-HBc+). All OBI cases (16/16) had HBV DNA VL < 10 IU/ml versus 37.5% (6/16) VL < 10 IU/ml, 25% (4/16) VL between ]10–500] IU/ml, and 37.5% (6/16) VL > 500 IU/ml among controls (overt infections). Genotyping was successful for 15.6% (5/32) participants with VL > 500 IU/ml (p = 0.02). Following genotyping, 80% (4/5) participants (VL > 2000 IU/ml) had at least one immune escape mutation (sT131N, sR122K, sG145A) and rtI169L mutation associated with drug resistance was detected in one donor. Molecular phylogeny revealed genotypes A (80%; 4/5) and E (20%; 1/5). HBV seropositivity was 25.1%, markedly higher than the estimated prevalence in the general population and therefore of significant concern. Likewise, the observed OBI prevalence of 5.7% represents a substantial risk to transfusion safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.